Compare Quest Diagnostics Inc (DGX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Vanguard Short Term Corporate Bond ETF trades at $78.52. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| DGX | VCSH | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Fixed Income |
52-Week High | $238.50 | $80.20 |
52-Week Low | $173.49 | $78.41 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
VCSH trades at $78.58, up 0.11% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF maintains a 4.8% yield with recent dividends of $0.29-$0.30, though credit spreads are tight. News highlights institutional activity, including Apella Capital reducing its stake by 5.6% in Q2 2026 (SEC filing, August 7, 2026).
Outlook is cautious due to unattractive entry points and limited upside from rate cuts, per Seeking Alpha (July 27, 2026). Risks include credit spread widening and competition from alternatives like BSV. The short 2.7-year duration offers some downside protection, but yield advantages may narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
